Immuno Therapy
2 Results were found on Technologies
Sub Category Name
Therapeutic Targeting of PD-1/PD-L1 blockade by Novel Small-molecule Inhibitors
Interactions between programmed cell death ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) lead to the evasion of cancer cells from an efficient immune response. The inhibition of PD-L1/PD-1 has prevented or reversed exhausted T cells, thus enhancing antitumor T-cell responses. In fact, immune checkpoint blockade targeting the PD-1 axis has become one […] Read More >
Therapeutic Targeting of CD45 by Novel Agents to Immunotherapy Non-Responders Tumors
Therapeutic advances in cancer immunotherapy have rapidly emerged in the past few years, reflecting the importance of the interaction between the human immune system and cancer. Despite the successful application of immunotherapy across a broad range of human cancers, only a minority of patients with terminal cancer experience life-altering durable survival from these therapies. These […] Read More >
